Cystatin B (CSTB) Gene Mutation Analysis
The CSTB gene that encodes Cystatin-B protein is located in chromosome 21 at position 22.3. Cystatin-B acts as an intracellular thiol protease inhibitor and inhibits the activities of papain, cathepsins l, h and b enzymes. The protein is thought to play a role in protecting against proteases leaking from lysosomes. One region of the CSTB gene has a particular repeating sequence (dodecamer repeat) of 12 DNA nucleotides and written as 5’-CCC-CGC-CCC-GCG-3’. This sequence is usually repeated two or three times and helps to regulate cystatin B protein production. Mutation in the CSTB gene by expansion in the promoter region of the dodecamer repeat from 2-3 copies to 30-78 copies causes progressive myoclonus epilepsy termed Unverricht–Lundborg Disease or EMP type 1 (EPM1). In this disease, the expanded dodecamer repeat in the CSTB gene appears to interfere with the production of cystatin B protein leading to an increase in intracellular cathepsin levels.
Clinically, EPM1 is an autosomal recessive neurodegenerative disorder characterized by its onset at 6–15 years, stimulus-sensitive myoclonus, tonic–clonic epileptic seizures and progressive neurologic deterioration to a variable degree. Symptoms include seizures with loss of consciousness, muscle rigidity, difficulty coordinating muscle movements (ataxia) and a decline in cognitive ability (dementia). Other mutations such as nonsense, missense, frameshift or splicing alterations may also occur in the CSTB gene.
- Aid in the diagnosis of Unverricht–Lundborg disease
- Differential diagnosis of Unverricht–Lundborg disease from other myoclonus epilepsy
- Testing of at-risk relatives for specific known mutation previously identified in an affected family member
- Useful in prenatal diagnosis for the known familial mutation(s) in at-risk pregnancies
Abnormal:
- Dodecamer repeat expansion in the promoter of CSTB >30 times (full penetrance allele) or mutations such as nonsense, missense, frameshift or splicing alterations in CSTB gene.
Normal:
- Normal repeats of dodecamer sequence (2-3 times) or no mutation in the CSTB gene
Note: Alleles of 12-17 dodecamer repeats have been observed, but individuals with alleles in this range have not undergone thorough clinical evaluation for signs and symptoms of EPM1
No mutation in the CSTB gene or normal repeat of dodecamer sequence (2-3 times)
Whole blood (EDTA/lavender top tub), buccal swab.
Stability
- Ambien: 5-7 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Eur J Hum Genet. 2007;15: 185-93. [PMID: 17003839]
- Epilepsy Behav Rep. 2019; 12: 100323. [PMID: 31463470]
- Genes (Basel). 2018; 9: 455. [PMID: 30208654]
- Epilepsy Res. 2012;99: 187-90. [PMID: 22154554]
- Eur J Hum Genet. 2005;13: 264. [PMID: 15483648]
- Epilepsia. 2004;45: 1061-3. [PMID: 15329070]
- Nature. 1997;386: 847-51. [PMID: 9126745]